biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector

VANCOUVER, BC--(Marketwired - November 29, 2015) - biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis or the "Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier ("BBB"), announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company's Transcend BBB delivery vector.

biOasis' Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97). Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would bind to specific receptors for this protein thus initiating transport across the BBB through a process known as Receptor Mediated Transcytosis. Work to show that this is indeed correct has resulted in issuance of a patent entitled "P97 Fragments with Transfer Activity."

"As our team worked with Transcend in pre-clinical models to prove its utility to delivery therapeutic agents across the BBB, they also conducted over four years of experiments to find active polypeptide fragments from within the 738 amino acid sequence of Transcend that were involved in binding specific receptors that are involved in transport through the BBB," said Rob Hutchison, CEO. "As we embarked down that lengthy process we made a number of discoveries. In 2010 we set in place a strategic plan to broaden and securely protect the assets of the Company; this patent was a key part of that journey. Intellectual Property patents are a key cornerstone to our commercial licensing strategy and as these patents issue, our license models increase in value, thereby increasing the overall value of the Transcend Platform."

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Richmond, B.C., Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The Company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.